Story
Dr. Reddy's Shares Rise on Takeda Dengue Vaccine Distribution Deal
Shares of Dr. Reddy’s Laboratories (NYSE:RDY) rose on Friday after the company announced a distribution agreement with Japanese drugmaker Takeda Pharmaceutical for its dengue vaccine, Qdenga.
The Agreement
Under the terms of the deal, Dr. Reddy’s will promote and distribute the Qdenga vaccine within India. The partnership is significant as Qdenga is the first-ever dengue vaccine to receive regulatory approval in the country.
The vaccine has been approved for use in both children and adults. According to the announcement, Dr. Reddy's anticipates that Qdenga will be commercially available in India during the first half of 2027.
Market Reaction
AdFollowing the news, Dr. Reddy’s stock climbed 1.8% to close at ₹1,196 in trading on India's National Stock Exchange. The company's shares outperformed the broader Indian market, as the benchmark Nifty 50 index posted a modest gain of just 0.1% during the same session.
Context for Investors
The deal positions Dr. Reddy's to tap into a critical public health need in India, where dengue fever is a widespread concern. The introduction of the country's first approved vaccine represents a potentially significant new market for the company, though revenue contributions are not expected until the planned 2027 launch.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.